[Taipei, Taiwan & Kobe, Japan] – CellTech Accelerator, the first cell and gene therapy accelerator in Asia, is pleased to announce the signing of a Memorandum of Understanding (MOU) with Cyto-Facto Inc., a prominent Japanese CDMO company specialized in manufacturing CGT products. The MOU sets the stage for collaborative efforts aimed at advancing the development and business growth of cell and gene therapy in the regions of Taiwan, Japan, and ASEAN countries.
Under the terms of the MOU, both parties will explore various avenues of cooperation with the goal of enhancing the landscape of the biotech industry.
Key areas of collaboration outlined in the MOU include:
- Business Development: Joint efforts will be made to facilitate the growth of cell and gene therapies in target regions through activities such as CDMO partnership, customized services, and consultation.
- CDMO Consultation Meetings: Consultation meetings will be conducted to address potential issues encountered by biotech companies. These meetings will serve as a platform for identifying and discussing challenges.
- Long-Term Service Agreements: The parties will explore the possibility of entering into long-term service agreements to address specific or complex process development issues faced by biotech companies.
- Co-Branding Initiatives: Both parties will collaborate on co-branding efforts across various platforms to amplify their presence and showcase their joint endeavors in the CGT industry.
For more information about CellTech Accelerator and Cyto-Facto Inc., please visit https://genecelltech.com and https://www.cytofacto.com/en/ respectively.